Today, Senator Ron Wyden and Congressman Earl Blumenauer introduced legislation to allow for interstate commerce when it comes to state-legal cannabis programs.
Illinois Gov. J.B. Pritzker has signed legislation legalizing the adult use of marijuana and regulating its commercial production and retail sale.
For the first time ever, the House of Representatives just voted to restrict the Department of Justice from interfering with the states that have legalized adult-use marijuana.
Join NORML with at least a $35 annual donation or sign up to be a sustaining $10 monthly donation before July 1 and we’ll send you this exclusive NORML drink koozie. Chances are, marijuana is safer than what’s in that can!
For the first time, the House Subcommittee on Financial Services and General Government Appropriations has included language seeking to protect the employment of federal employees who consume cannabis in legal jurisdictions.
Doug was a passionate advocate for ending America’s failed war on cannabis consumers, and his work with NORML and for the cause spans decades not years. This is a sad loss for his friends and family, the New York cannabis community, and the legalization movement.
In its written testimony, NORML Deputy Director Paul Armentano encourages the agency to act expeditiously to clarify confusion among both consumers and regulators with regard to the legality of specific CBD products. It further recommends that the FDA provide regulatory guidelines governing product manufacturing, standardization, and quality.
After decades of hard work by dedicated volunteers and activists from coast-to-coast that mission is one step closer to fruition following the passage of the Cannabis Regulation and Tax Act (HB1438-SFA2) by the Illinois Senate.
The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry. Commenting on the study’s findings, NORML Deputy Director Paul Armentano said, “These conclusions add to the growing body of evidence that cannabis and its constituents represent an exit away from the use or abuse of other controlled substances rather than a supposed ‘gateway.'”
NORML has submitted written comments to the US Food and Drug Administration ahead of the agency’s scheduled hearing on the regulation CBD-infused products. The agency will be taking in person public testimony on Friday, May 31, with regard to the “manufacturing, product quality, marketing, labeling, and sale” of CBD-infused retail products.